Exchange: NASDAQ Sector: Healthcare Industry: Biotechnology
0.31% $3.26
America/New_York / 26 apr 2024 @ 14:37
FUNDAMENTALS | |
---|---|
MarketCap: | 7.33 mill |
EPS: | -2.66 |
P/E: | -1.230 |
Earnings Date: | May 08, 2024 |
SharesOutstanding: | 2.25 mill |
Avg Daily Volume: | 0.573 mill |
RATING 2024-04-26 |
---|
C |
Sell |
RATINGS | ||
---|---|---|
Rating CashFlow: | Buy | |
Return On Equity: | Strong Sell | |
Return On Asset: | Strong Sell | |
DE: | Strong Sell | |
P/E: | Sell | |
Price To Book: | Sell |
QUARTER GROWTHS | ||||||
---|---|---|---|---|---|---|
3/22 | 4/22 | 1/23 | 2/23 | 3/23 | 4/23 | |
Revenue | n/a | n/a | n/a | n/a | n/a | n/a |
Gr.Profit | n/a | n/a | n/a | n/a | n/a | n/a |
Ebit | ||||||
Asset | ||||||
Debt | n/a | n/a | n/a | n/a | n/a | n/a |
PE RATIO: COMPANY / SECTOR |
---|
0.00x |
Company: PE -1.230 | sector: PE -3.05 |
PE RATIO: COMPANY / INDUSTRY |
---|
-0.21x |
Company: PE -1.230 | industry: PE 5.88 |
DISCOUNTED CASH FLOW VALUE |
---|
$2.19 (-32.70%) $-1.066 |
Date: 2024-04-26 |
Expected Trading Range (DAY) |
---|
$ 2.83 - 3.69 ( +/- 13.31%) |
ATR Model: 14 days |
Date | Person | Action | Amount | type |
---|---|---|---|---|
2023-09-26 | Van Der Baan Bastiaan Jeroen | Buy | 250 000 | Options to Purchase Common Stock |
2023-10-03 | Bernards Rene | Buy | 5 527 | Common Stock |
2023-10-02 | Bernards Rene | Buy | 4 473 | Common Stock |
2023-10-03 | Van Der Baan Bastiaan Jeroen | Buy | 10 000 | Common Stock |
2023-10-02 | Bernards Rene | Buy | 4 473 | Common Stock |
INSIDER POWER |
---|
100.00 |
Last 91 transactions |
Buy: 9 375 819 | Sell: 3 494 167 |
Indicator Signals | |
---|---|
RSI 21 | |
SMA | |
Trend | |
Trend 2 | |
Trend 3 | |
MACD |
Volume Signals | |
---|---|
Price | $3.26 (0.31% ) |
Volume | 0.0041 mill |
Avg. Vol. | 0.573 mill |
% of Avg. Vol | 0.710 % |
Signal 1: | |
Signal 2: |
0 Signals | Accuracy: 0.00% | Accuracy Buy: 0.00% | Accuracy Sell: 0.00%
Avg return buy: 0.00 % | Avg return sell: 0.00 %
$1 invested is now $1.00 or 0.00% since Coming Soon
Date | Signal | @ | Closed | % |
---|
Lixte Biotechnology Holdings, Inc. operates as a drug discovery company that uses biomarker technology to identify enzyme targets related with serious common diseases and designs novel compounds to attack those targets. The company primarily focuses on inhibitors of protein phosphatases that are used alone and in combination with cytotoxic agents and/or x-ray and immune checkpoint blockers; and encompasses two major categories of compounds at various stages of pre-clinical and clinical development. It develops two series of pharmacologically active drugs, which include the LB-100 series that consists of novel structures for the treatment of cancers, and vascular and metabolic diseases; and LB-200 series to treat chronic hereditary diseases, such as Gaucher's disease, as well as cancer and neurodegenerative diseases. Lixte Biotechnology Holdings, Inc. has a clinical trial research agreement with the Moffitt Cancer Center and Research Institute Hospital Inc.; collaboration agreement for an investigator-initiated clinical trial with the Spanish Sarcoma Group, as well as Netherlands Cancer Institute and Oncode Institute. The company was founded in 2005 and is based in Pasadena, California.